Legislation & Regulation

Newly elected UK Labour leader, Jeremy Corbyn, has appointed Luciana Berger to his shadow cabinet as the “Minister for Mental Health,” a new position that has no counterpart in the Conservative government. The Independent reports that Corbyn has devoted considerable attention to mental health issues.

Individuals between the ages of 15 and 24 are more likely to commit a violent crime if they are taking an SSRI antidepressant than if they are not, according to new research out of Sweden. The study published in PLoS Medicine on Tuesday, suggests "warnings about the increased risk of violent behavior among young people taking SSRIs might be needed.”

Huffington Post and journalist Steve Brill have combined to launch a 15 part series about how Johnson & Johnson illegally violated FDA restrictions by pushing the antipsychotic drug, Risperdal, for use with adolescents and the elderly. The series, entitled “America’s Most Admired Lawbreaker,” launched yesterday and will include mixed media, videos, podcasts, source documents, as well as 15 written chapters. Click more for a synopsis of part 1.

New research published in the August issue of Psychiatric Annals evaluates the results of randomized control trials on the use of various psychotropic drugs for patients diagnosed with borderline personality disorder (BPD). Despite the “American Psychiatric Association’s practice guidelines endorsement of SSRIs as first-line therapies for BPD,” the results of the meta-analysis reveal that pharmacotherapy in BPD is “not supported by the current literature,” and “should be avoided whenever possible.”

Last Thursday, the FDA agreed to review a “digital pill,” combining a sensor with the antipsychotic Abilify, in order to track patients’ compliance with drug treatment. Patients taking the tracker pill would also wear a patch, which would receive information and relay it to a mobile device, according to a brief report by BioPharmaDIVE.

Thirty-three percent of all inmates in New Mexico are taking at least one psychotropic drug. The rate is up from 25% in 2013, according to a report by The Santa Fe New Mexican. While the prescription rate at the federal level is 10%, 30% of male inmates and 70% of female inmates in New Mexico are prescribed psychotropic drugs.

“In Gallup's annual measure of 25 major U.S. business sectors, the percentage of Americans with a positive view of the pharmaceutical industry dropped from 40% in 2014 to 35% this year, while the percentage with a negative view rose from 36% to 43%.”

In exchange for pleading guilty to murder, a young soldier received a 45-year sentence with the possibility of parole. The plea resulted from evidence that Chantix, a smoking cessation drug manufactured by Pfizer, can increase hostility and agitation, according to the SunHerald. “Several experts provided some evidence that Chantix affected (the soldier’s) ability to appreciate the nature and quality or wrongfulness of his acts,” the SunHerald noted.

When Wilda White recovered from a manic episode triggered by her ADHD medication, she had lost her relationship, her home, and her dream job as a public interest lawyer. She reached a turning point when, she told Seven Days newspaper, "in the course of trying to figure out what had happened to me, I went on the website Mad in America.” Through the site, she connected with a job listing from Vermont Psychiatric Survivors, a non-profit dedicated to empowering and protecting the rights of people labeled “mentally ill.” She is now their executive director.

According to an analysis by the Washington Post, “On average, police shot and killed someone who was in mental crisis every 36 hours in the first six months of this year.” Chuck Wexler, executive director of the Police Executive Research Forum called it “a national crisis.” “We have to get American police to rethink how they handle encounters with the mentally ill. Training has to change.”

Amid growing criticism about the over-prescription of psychotropic medication in foster care, Pennsylvania commissioned PolicyLab to conduct an analysis of the use of psychiatric drugs among all of the state’s Medicaid-enrolled children. The report, released in June, found that the rate of psychotropic prescriptions among youth in Medicaid and foster care was higher than previously reported.

New York State has investigated five large insurance companies for violating state and federal mental health parity laws by illegally denying to cover claims for behavioral health conditions and drug abuse treatment, according to a report by North County Public Radio (ncpr).

Antipsychotics are being prescribed to people who may have challenging behaviors but no mental disorder, according to new research published in this month’s issue of BMJ. “Excessive use of psychotropic drugs has individual and systemic implications,” the researchers write. “Antipsychotics, in particular, are associated with several adverse side effects that can impair quality of life and lead to deleterious health outcomes.”

Psych Central covers findings published in BMJ revealing that many people in the U.K. with intellectual disabilities are being prescribed antipsychotic drugs. The study’s lead author comments: “People who show problem behaviors, along with older people with intellectual disability or those with co-existing autism or dementia, are significantly more likely to be given an antipsychotic drug, despite this being against clinical guidelines and risking possible harm.”

This month’s issue of JAMA Psychiatry ran an editorial commenting on recent research revealing that the majority of youth prescribed antipsychotics have not been diagnosed with a mental disorder.

In the September issue of The Journal of the American Medical Association (JAMA) three FDA advisory committee members describe the convergence of factors that made the committee’s recommendation to approve flibanserin especially challenging and politically charged.

On Tuesday, NPR told the story of DeAngelo Cortijo. DeAngelo became a foster kid at age 3 after his mother attempted suicide. He was “diagnosed with bipolar and anxiety disorders, attachment disorder, intermittent explosive disorder or posttraumatic stress disorder,” and was prescribed “a combination of antipsychotics, antidepressants and stimulants, and was told that taking them was his only hope of being normal.” Through equine therapy, DeAngelo was eventually able to get off all of his medication. Now, California is hoping to pass reforms that would prevent foster kids, like DeAngelo, from being “prescribed antipsychotic drugs at double to quadruple the rate of that not in foster care.”

MedPageToday reports that Janssen Pharmaceuticals omitted data from a 2003 study that connected Risperdal with serious side effects. Janssen was previously sued by the FDA for marketing Risperdal for off-label uses and settled for $2.2 billion in 2013. Earlier this year, a man with autism was awarded $2.5 million after growing breasts while on Risperdal. According to MedPage, documents from this latest case reveal missing data tables from a 2003 study “designed to ferret out potential adverse effects of long-term risperidone use.” The missing tables were related to elevated prolactin levels and side effects, including gynecomastia in men.

Parents Opposed to Pot, a group opposed to the legalization of marijuana, criticizes a recent University of Pittsburgh study which found no correlation between pot use and mental health. They contest the results and insist that since the long-term study began in 1987, “skunk” or high THC pot has been on the rise.

An editorial in the Guardian discusses the fact that the number of people with intellectual or learning disabilities “who are being treated with psychotropic drugs far exceeds those with mental illness.” The authors of a new study examining the overuse of psychotropic drugs on people with learning disabilities, published this month in BMJ, argue: “If people without mental illness are given psychotropic drugs… it is probably to control their behavior.”

Writing for Forbes, Matthew Herper documents the FDA’s increasing drug approval rates. “In 2008, BioMedTracker says the FDA approved 20 new molecular entities (NMEs) and rejected 20, for an approval rate of 50%.” So far this year, he writes, “the FDA approval rate is more like 96%.”

Jeffrey Lieberman, past-president of the American Psychiatric Association, authored an Op-Ed in last Friday’s New York Times, calling for improved mental health screenings in schools and emergency rooms in the wake of the murder of Virginia journalists Alison Park and Adam Ward. In support of forced treatment mechanisms, Lieberman claims: “Almost every mentally ill perpetrator of mass violence had been symptomatic and untreated for lengthy periods of time before their crime, because they (or their families) did not seek treatment or they refused it.”

The International Business Times covers a new study showing “trials for new antidepressant medications may not be applicable to the population at large.” “The finding, published in the Mayo Clinic Proceedings, shows recent trials are less generalizable than the prior studies, as researchers excluded most depressed patients from drug company-sponsored treatment studies.”

Writing for Truth-Out, hurricane Katrina survivor G. Maris Jones writes: “To adapt to a changing climate, survivors of these catastrophes - especially those in marginalized, low-income communities - need long-term physical and mental health services.” She adds a concurrent call to “assume our responsibility to make positive change through action on climate change.”

CBC News Canada voices sex therapists and psychiatrists concerns over the FDAs decision to approve Flibanserin last week. Critics contend, “it's an ineffectual pharmacological solution for a problem better treated with relationship counselling, sex therapy and behavioural changes.” Walid Gellad, the co-director of the Center for Pharmaceutical Policy and Prescribing adds, “"[I] believe that it should be used by almost no one.”